Immunovant (IMVT) Accumulated Expenses (2018 - 2026)

Immunovant has reported Accumulated Expenses for 9 years, with the latest figure at $96.6 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses rose 90.42% year-over-year to $96.6 million; the trailing twelve-month figure through Mar 2026 stood at $96.6 million (up 90.42% YoY), and the FY2026 full-year result was $96.6 million, up 90.42% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $96.6 million, up from $57.6 million in the prior quarter.
• The five-year high for Accumulated Expenses was $96.6 million in Q1 2026, with the low at $19.0 million in Q2 2022.
• Historically, Accumulated Expenses has averaged $40.8 million across 5 years, with a median of $40.4 million in 2023.
• Annual changes were most pronounced in 2022 — Accumulated Expenses dropped 17.16% — and 2026, when it jumped 90.42%.
• Immunovant's Accumulated Expenses stood at $26.0 million in 2022, then advanced by 7.05% to $27.9 million in 2023, then surged by 73.84% to $48.5 million in 2024, then grew by 18.91% to $57.6 million in 2025, then surged by 67.65% to $96.6 million in 2026.
• The last three Accumulated Expenses figures came in at $96.6 million (Q1 2026), $57.6 million (Q4 2025), and $56.3 million (Q3 2025), per Business Quant data.